neuroblastoma – Medxy AI

Pilot Study: Busulfan-Based Haploidentical Stem Cell Transplantation Plus GD2 Antibody Therapy for High-Risk Neuroblastoma

By MedXY 06/04/2026

A small pilot study found that busulfan-based haploidentical stem cell transplantation followed by dinutuximab beta was feasible and may improve long-term remission in very high-risk neuroblastoma.

Clinical Updates news Oncology Pediatrics

Long-Term Thyroid Toxicity Burden in Children Who Received Treatment for High-Risk Neuroblastoma

By MedXY 03/11/2026

This review analyzes the significant long-term thyroid toxicity burden in high-risk neuroblastoma survivors, identifying key risk factors such as molecular radiotherapy, tandem myeloablative therapy, and immunotherapy.

news Oncology Pediatrics

Optimizing Anti-GD2 Immunotherapy: Dinutuximab Beta Redefines Survival in Relapsed and High-Risk Neuroblastoma

By MedXY 01/20/2026

Recent clinical trials establish dinutuximab beta as a cornerstone of neuroblastoma therapy, demonstrating significant survival benefits when combined with chemotherapy in relapsed cases, while clarifying that adding Interleukin-2 to standard consolidation increases toxicity without improving outcomes.

$A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children$

Clinical Updates news Oncology Specialties

A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children

By MedXY 08/05/2025

A phase I trial published in JCO demonstrates that a novel combination of MIBG, dinutuximab, and vorinostat achieves up to 75% disease control in relapsed/refractory neuroblastoma, offering new hope for high-risk pediatric patients.